Exact Mass: 365.0071
Exact Mass Matches: 365.0071
Found 60 metabolites which its exact mass value is equals to given mass value 365.0071,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Fludarabine
Fludarabine is only found in individuals that have used or taken this drug. Fludarabine (marketed as fludarabine phosphate under the trade name Fludara) is a chemotherapy drug used in the treatment of hematological malignancies. [Wikipedia]Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis. The mechanism of action of this antimetabolite is not completely characterized and may be multi-faceted. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.
Fludara
D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents
2-Hydroxy-4-(2-(tosyloxy)acetamido)benzoic acid
3-(3,5-dibromo-4-methoxyphenyl)-2-methoxy-N-methylpropan-1-amine
Fludarabine phosphate
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2150 - Ribonucleotide Reductase Inhibitor D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents D009676 - Noxae > D000963 - Antimetabolites D000970 - Antineoplastic Agents Fludarabine (phosphate) is an analogue of adenosine and deoxyadenosine, which is able to compete with dATP for incorporation into DNA and inhibit DNA synthesis.
1-chloro-N-(2-(ethylsulfonyl)-5-(trifluoromethyl)phenyl)methanesulfonamide
1-(4-bromo-2-phenylmethoxyphenyl)-N-phenylmethanimine
Pyrido[1,2-a]benzimidazole, 1,2,3,4-tetrahydro- (6CI,7CI,8CI,9CI)
Glucantime
P - Antiparasitic products, insecticides and repellents > P01 - Antiprotozoals > P01C - Agents against leishmaniasis and trypanosomiasis > P01CB - Antimony compounds D000890 - Anti-Infective Agents > D000977 - Antiparasitic Agents > D000981 - Antiprotozoal Agents
3-BROMO-N-(3,3-DIETHOXY-PROPYL)-BENZENESULFONAMIDE
5-(6-Bromonaphthalen-2-yl)-2,2-dimethyl-5-nitro-1,3-dioxane
6-BROMO-5-(2-FLUORO-4-NITROPHENOXY)-1-METHYL-1H-INDAZOLE
3-ETHYL-2-METHYL-5-PHENYL-BENZOOXAZOL-3-IUM IODIDE
Luxabendazole
C254 - Anti-Infective Agent > C276 - Antiparasitic Agent > C250 - Antihelminthic Agent
Bis(trifluoro-2,4-pentanedionato)cobalt(II) Hydrate
1(2H)-Pyridinecarboxylic acid, 3,6-dihydro-4-[[(trifluoromethyl)sulfonyl]oxy]-, phenylmethyl ester
3-(N-(4-CHLORO-3-METHYLISOXAZOL-5-YL)SULFAMOYL)-N-METHOXY-N-METHYLTHIOPHENE-2-CARBOXAMIDE
(2,3,4,5,6-pentafluorophenyl) 6-phenylpyridine-3-carboxylate
2-(2-Hydroxy-4-benzoyloxyphenyl)-5-chlorobenzotriazole
3-(2-CHLORO-6-FLUOROPHENYL)-N-(2-CHLORO-3-PYRIDINYL)-5-METHYL-4-ISOXAZOLECARBOXAMIDE
O,O-Diethylphosphoryl (Z)-2-(2-aminothiazol-4-yl)-2-acetyloxyiminoacetate
N-[4-(2,4-dichlorophenoxy)-6-(trifluoromethyl)-2-pyrimidinyl]-N-isopropylamine
2-({[4-(Trifluoromethoxy)phenyl]sulfonyl}amino)ethyl Dihydrogen Phosphate
Orotidine 5-phosphate(3-)
COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS
acetamidomethyl-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(phosphonooxymethyl)oxolan-2-yl]oxyphosphinic acid
1-[4-(4-Bromophenyl)-2-thiazolyl]-4-piperidinecarboxamide
4-Cyanobenzoic acid [4-oxo-6-[(2-pyrimidinylthio)methyl]-3-pyranyl] ester
N-[3-(1,3-benzothiazol-2-yl)-4,5,6,7-tetrahydrothieno[2,3-c]pyridin-2-yl]-2,2-difluoroacetamide
1-(3,4-Dichlorophenyl)-3-(5-pyridin-4-yl-1,3,4-thiadiazol-2-yl)urea
3-(benzenesulfonyl)-N-[5-(trifluoromethyl)-1,3,4-thiadiazol-2-yl]propanamide
5-(2,5-dichlorophenyl)-N-(2-propyl-5-tetrazolyl)-2-furancarboxamide
5-ethyl-N-[[2-(3-pyridinyl)-4-thiazolyl]methyl]-2-thiophenesulfonamide
ethyl 2-{[(1E)-(4,6-dioxo-2-thioxohexahydropyrimidin-5-yl)methylene]amino}-5,6-dihydro-4H-cyclopenta[b]thiophene-3-carboxylate
Methyl 2-O-chlorobenzoyl-4-chloro-N-methyloxalonilate
Orotidine 5-phosphate(3-)
Trianion of orotidine 5-phosphate arising from deprotonation of carboxylic acid and phosphate functions.
BMS-986121
BMS-986121 is a positive allosteric modulator (PAM) of the μ opioid receptor extracted from patent WO2014107344. BMS-986121 is built on a chemical scaffold representing a new chemotype for μ receptor PAMs[1][2][3].
HIF-2α-IN-2
HIF-2α-IN-2 is a hypoxia-inducible factors (HIF-2α) inhibitor extracted from patent WO2015035223A1, Compound 232, has an IC50 of 16 nM in scintillation proximity assay (SPA)[1].
